Recruiting
Real World Observational Study of Sotatercept for Pulmonary Hypertension
The purpose of this study seeks to describe the real world initial experience with sotatercept in the treatment of pulmonary hypertension.
ClinicalTrials.gov IDNCT06751082
PhaseNot Applicable
Enrollment120
SponsorMayo Clinic
Age18 Years
SexALL
Conditions studied
Pulmonary Hypertension
About this study
The purpose of this study seeks to describe the real world initial experience with sotatercept in the treatment of pulmonary hypertension.
Primary outcomes
- EmPHasis10 Questionnaire (Baseline, Year 1, Year 2, Year 3, Year 4, Year 5, Year 6, Year 7, Year 8, Year 9, Year 10)
- Number of pulmonary hypertension vasodilator medications taken by a subject (Baseline, Year 10)
- Number of patients to have a change in dose of prostanoid medications (Baseline, Year 10)
- Number of patient hospitalizations (Baseline, Year 10)
- Number of patients to cease therapy sessions (Baseline, Year 10)
- Number of patients to discontinue prostanoid therapy (Baseline, Year 10)
- Number of patients with bleeding complications (Baseline, Year 10)
- Number of patients to develop Skin telangiectasias (Baseline, Year 10)
Eligibility information
Inclusion Criteria:
* Adults age 18 or greater who are being treated with sotatercept in the Mayo Pulmonary hypertension clinic.
Exclusion Criteria:
* Adults lacking capacity to consent
Study locations
- Mayo Clinic, Rochester, Minnesota 55905 United States
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.